FDA reports cancer risk associated with heartburn drugs Zantac and ranitidine.
Zantac (ranitidine) is an over-the-counter medication taken to control the symptoms associated with acid reflux, gastric ulcers, and gastroesophageal reflux (GERD). Zantac, and its generic equivalent ranitidine, has been shown to contain a cancer-causing compound, NDMA (N-nitrosodimethylamine), prompting stores to pull the product from the shelves. Sandoz, Inc. has issued a recall of Zantac and generic versions of ranitidine to prevent further public exposure to the cancer-causing agent.
Studies have linked NDMA, the potential contaminant in Zantac to:
- Bladder cancer
- Colorectal cancer
- Esophageal cancer
- Intestinal cancer
- Kidney cancer
- Liver cancer
- Ovarian cancer
- Pancreatic cancer
- Stomach cancer
- Testicular cancer
- Uterine cancer
In 1987, 6 years after Zantac was introduced as a prescription medication, it topped the list of drug sales and produced profits for GlaxoSmithKline. Zantac became an over-the-counter drug in 2006. Studies by Stanford University and the National Cancer Institute found ranitidine links to bladder cancer as early as 2004. The drug testing company, Valisure, reports that each product tested that included ranitidine produced levels of NDMA in excess of the FDA safe levels.
If you have taken Zantac or ranitidine, and have developed cancer, Davis & Crump is ready to help you. You may be eligible for compensation for medical bills, lost wages, permanent or temporary disability, or pain and suffering.
Contact us for a free claim evaluation.. Our attorneys are experienced in taking on complex pharmaceutical litigation. Call us at 1-800-277-0300 or email us at info@daviscrump.com. There is no fee unless we win a recovery for you.
Fill out a free claim evaluation or call us at 1-800-277-0300 to get started.
